<DOC>
	<DOCNO>NCT01954693</DOCNO>
	<brief_summary>This single centre , two-arm , individually randomise , Phase II , double- blind , placebo-controlled trial RAD001 ( Everolimus ) versus placebo treatment neurocognitive problem patient tuberous sclerosis ( TSC ) . The IMP license medicine patient group different target effect . The current trial proof principle study memory executive function outcome . Following eligibility visit , patient schedule baseline visit randomization . They follow 6 month undergo safety neurocognitive assessment whilst take either placebo study drug . 48 patient age 16 60 year tuberous sclerosis ( TSC ) IQ &gt; 60 significant deficit one primary outcome measure randomly allocate ratio 2:1 either RAD001 ( Everolimus ) Placebo .</brief_summary>
	<brief_title>A Study Everolimus Treatment Neurocognitive Problems Tuberous Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Definite TSC current clinical criterion ( 28 ) ; 2 . Male female age 16 60 yr ; 3 . IQ 60 Wechsler Abbreviated Scales Intelligence ( WASI ) able participate direct neuropsychological test ; 4 . A score fall , , 5th percentile ( approximately equivalent 1.5 SD ) one primary outcome measure : 5 . Calculated GFR &gt; 60ml/min/1.73m2 except case renal impairment associate TSC complicate kidney , calculate GFR ≥30ml/min/1.73m2 ; 6 . INR 1.5 le ( anticoagulation permit target INR stable dose warfarin LMW heparin &gt; 2 week time randomisation ) ; 7 . Adequate liver function show : serum bilirubin less equal 1.5 x ULN , ALT AST less equal 2.5 x ULN ; 8 . If sexually active negative pregnancy test female time inform consent , contraception male premenopausal female study ) ; 9 . Seizure free stable seizure define change type AEDs 6 month prior full recruitment randomization baseline . Doses drug may change 6 month prior recruitment ; 10 . Hepatitis B surface antigen negative , Hepatitis C antibody negative . 11 . All patient must able communicate well investigator , understand comply requirement study , understand sign write informed consent ; 12 . Female patient childbearing potential must prepare use two acceptable method contraception , ( e.g. , intrauterine device plus condom , spermicidal gel plus condom , diaphragm plus condom , etc . ) , time screen . 1 . Prior treatment mTOR inhibitor ; 2 . Investigational agent &lt; 30 day prior randomisation ; 3 . Surgery last 2 month ; 4 . Previous brain neurosurgery ; 5 . Significant haematological abnormality i.e . haemoglobin &lt; 8g/dL , platelet &lt; 80,000/mm3 , absolute neutrophil count &lt; 1000/mm3 ) ; 6 . Urine protein/creatinine &gt; 0.02g/mmol except case renal impairment associate TSC complication kidney , urine protein/creatinine ratio &gt; 0.1g/mmol exclusion ; 7 . Serum creatinine &gt; 1.5 x ULN except case renal impairment associate TSC complication kidney , serum creatinine &gt; 300µmol/L exclusion ; 8 . Uncontrolled hyperlipidaemia ( fast cholesterol &gt; 300mg/dL &gt; 7.75 mmol/L fast triglyceride &gt; 2.5 x ULN , diabetes fast serum glucose &gt; 1.5 x ULN ; 9 . History myocardial infarction , angina stroke related atherosclerosis , significant cardiac disease , HIV seropositivity , organ transplant , malignancy squamous basal cell skin cancer ; 10. lymphangioleiomyomatosis FEV1 &lt; 70 % predict , restrictive pulmonary disease ; 11 . Bleeding diathesis oral antivitamin K medication low dose warfarin ; 12 . Pregnancy/lactation ; 13 . Live vaccine require trial ; 14 . Use strong inhibitor CYP3AE ; 15 . Use strong inducer CYP3AE except anti epileptic drug ; 16 . Intercurrent infection time randomisation ; 17 . Inability complete study material ( outcome measure ) English ; 18 . History significant traumarelated cognitive deficit ; 19 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption Everolimus ( e.g . pancreatic insufficiency ) ; 20 . Known sensitivity Everolimus Rapamycin analogues excipients ; 21 . Inability attend schedule visit .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Tuberous Sclerosis</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Neurocognitive functioning</keyword>
</DOC>